globenewswire.com/news-release/2018/10/15/1621519/0/en/Aclaris-Therapeutics-to-Acquire-Worldwide-Rights-to-RHOFADE-from-Allergan.html

Oct 15, 2018 ... Allergan has agreed to provide support to Aclaris to allow for a smooth ... entering into a loan and security agreement with Oxford Finance LLC.

www.fiercepharma.com/pharma/allergan-names-new-cfo-as-it-works-its-way-through-financial-steeplechase

Feb 5, 2018 ... Allergan, which is maneuvering through a host of financial challenges, has landed a new CFO who can help figure out how to pay for the fixes ...

www.annualreports.com/HostedData/AnnualReportArchive/a/NYSE_AGN_2003.pdf

ed to the purchase of Bardeen Sciences Company, LLC, 3) $0.4 million reversal of .... In this Annual Report, Allergan included historical non-GAAP financial ...

investorplace.com/2018/12/why-agn-stock-is-down

Dec 20, 2018 ... Allergan (NYSE:AGN) is no longer selling its breast implants in the ... Hugh- Jones, Chief Medical Officer for Allergan, told Yahoo Finance.

seekingalpha.com/article/4063057-allergan-triumph-financial-engineering-reality

Apr 18, 2017 ... Allergan's so-called performance net income is a cash flow measure, not a net income measure. Allergan has thumbed its nose at the SEC, ...

myfloridalegal.com/webfiles.nsf/WF/MNOS-AYSNE3/$file/Complaint.pdf

May 15, 2018 ... Inc., Teva Pharmaceutical Industries Ltd., Allergan plc, Allergan Finance, LLC, Actavis PLC,. Filing # 72158675 E-Filed 05/15/2018 12:57:36 ...

money.cnn.com/quote/forecast/forecast.html?symb=AGN

The 19 analysts offering 12-month price forecasts for Allergan plc have a ... are registered trademarks of Standard & Poor's Financial Services LLC and Dow ...

www.insurancejournal.com/news/national/2018/08/08/497431.htm

Aug 8, 2018 ... Allergan Plc on Thursday sued Pfizer Inc. to require its rival to cover any ... responsibility to indemnify Allergan,” alleged Allergan Finance LLC, ...

www.investmentnews.com/article/20180709/FREE/180709937/judge-dismisses-stock-drop-suit-against-allergan

Jul 9, 2018 ... The plaintiffs argued Allergan's stock was artificially inflated because ... that Allergan lacked "effective internal controls" over financial reporting.